Pharmafile Logo

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

- PMLiVE
The US government passed the Orphan Drug Act in 1983, and it was subsequently adopted in other key markets, most notably in Japan in 1993 and the European Union in 2000. Growth in this sector has remained around 12% annually, which is more than double that experienced in the general drug market. According to the 2015 Orphan Drug Report, worldwide orphan drug sales will reach $178 billion by 2020 and will account for 20% of all prescription drug sales by 2020*. 

The trend is clear: as science and technology advances, and the rise of the internet and social media enables patients and researchers to gather and share information more effectively, we are seeing treatments for rare diseases that only a few years ago would have led to an early death. 

Alison Cantle, Rare Disease Business Unit Director at Lucid Group, explains what this means for medical education agencies: “As pharmaceutical organisations focus on personalised medicine, the need for rare disease expertise in their medical education agencies is paramount. Lucid recognised this and structured its business last year to create a unit specialising in rare diseases.” 

Within this unit, Lucid Group had recruited a team of highly skilled medical writers who combine a deep and robust understanding of the science with experience of working with rare disease specialists across the globe.

“Our rare disease team understands the cornerstones of rare disease education and what makes it different from other therapy areas. It is essential to build networks and enable best practice sharing,” Alison explains. “And in rare disease, more so than in any other therapy area, the choice of agency is crucial, as often it is your agency who represents your organisation at the communication level – so its voice has to be your voice.” 

Patients who have a rare disease face difficulty in every step of medical care, including diagnosis, treatment and preserving quality of life. Sometimes, patients go years without receiving the correct diagnosis for their condition. So raising awareness, improving time to diagnosis, getting patients to the right care, and improving family and emotional support and reimbursement are just some of the areas where medical education agencies can support pharma clients. 

Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease, cystinosis and PKU.  For further information about working with Lucid’s Rare Disease Business Unit, please call Alison on 01494 552078 or email alison@lucid-uk.com. 

* EvaluatePharma Orphan Drug Report 2015

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

#LucidLife is just about to get better with the move to Middlesex House

With only a few weeks to go Jan Steele, Lucid co-founder and COO discusses how the move to Middlesex House supports its commitment to making Lucid a great place to...

Lucid Group has four programmes shortlisted for PMEA 2019

Lucid is celebrating four of their programmes being shortlisted in four categories at this year's PMEAs

The heart of Lucid’s new HQ is under construction

With just 3 weeks until the move, the new kitchen and bar are being installed in Middlesex House.

Bluedog boosts its senior team with the appointment of its new Technical Director

Bluedog, a Lucid Group company, is set to create more magic for its clients with the appointment of Jonathan Andrew as its new technical director.Jonathan has a proven track record...

HealthCare21 experience the Lucid magic at its Engagement Day

Yesterday was a big step forward in the integration of HealthCare21 into Lucid Group.  Everyone from the HealthCare21 team attended the Engagement Day at Quarry House Mill, Macclesfield.The aim was to...

Lucid Group start the countdown to its big move

One month to go until Lucid Group moves into their new London Headquarters

Lucid Group increases footprint in UK, Asia Pacific and Middle East with the acquisition of HealthCare21

Lucid Group is delighted to announce its latest acquisition, welcoming colleagues from Healthcare consultancy HealthCare21 into its magic kingdom.Over the last twelve years, Lucid Group has become well known and...

Lucid Group Lucky Lunches prove a spellbinding hit this summer

Lucid Group Lucky Lunches have been running throughout the summer months, giving our teams the chance to network and connect outside of the office - as well as enjoying a...

Lucid’s Summer Fridays Shone

Lucid Group has been enjoying long weekends throughout the summer thanks to Summer Fridays, a concept introduced in line with Lucid’s agile working policy.Employees have been encouraged to spread their...

Celebrating Ten Magical Years with Clare Reynolds

Lucid loves to recognise and celebrate the magic people create for their clients, teams and patients. This month it was time to recognise the outstanding contribution that Clare Reynolds has...